Rare Lymphoma Risk Haunts Remicade Expansion To Pediatric Ulcerative Colitis
Determining how to handle the risk of rare, but deadly, hepatosplenic T-cell lymphoma with Centocor’s Remicade (infliximab) will be one of the tasks FDA faces as it decides whether to expand the biologics’ indication for ulcerative colitis to pediatric patients.
You may also be interested in...
FDA’s Gastrointestinal Drugs Advisory Committee is scheduled to review Abbott’s sNDA for the TNF blocker Humira Aug. 28.
Manufacturers must conduct in-depth follow-up of reported malignancies in children and young adult patients and submit them to FDA within 15 days of learning about the cases.
Recent waivers allowing the participation of outside experts at drug-related advisory committee meetings reflect FDA's difficulties in finding qualified individuals to provide advice on specialized topics.